Orforglipron Dosage: Doses Studied, Units and Chart
What doses of Orforglipron have been used in published research, how they convert to syringe units, and what is still unknown.
- Doses studied
- 12 studies
- with a stated dose, listed below
- Frequency
- Varies by study
- as used in studies
- Half-life
- approximately 29 to 49 hours
- oral, in people · FDA label (Foundayo)
Dosing on the FDA label
Quoted from the approved product label. It applies to the approved product used as prescribed, not to compounded or research-chemical versions.
- Administration: orally once daily, with or without food · FDA label (Foundayo)
- Missed doses: re-escalate after 7 or more missed doses · FDA label (Foundayo)
- Maximum dose with a strong CYP3A4 inhibitor · FDA label (Foundayo)
Doses used in published studies
Each dose below is quoted from a study abstract, strongest design first. Animal doses are labelled and do not translate directly to people. None of them is a recommendation.
| Dose | Frequency and route | Study type | Source |
|---|---|---|---|
| 6 mg, 12 mg, 36 mg | once-daily · oral · 72 weeks | Human RCTn = 1613 | Lancet 2026, PMID 41275875 |
| orforglipron 12 mg or 36 mg vs oral semaglutide 7 mg or 14 mg | once per day · oral · 52 weeks | Human controlled trialn = 1698 | Lancet 2026, PMID 41765029 |
| orforglipron 3 mg, 12 mg or 36 mg vs dapagliflozin 10 mg | once-daily · oral · 40 weeks | Human controlled trialn = 962 | Lancet 2026, PMID 42259339 |
| 5.5 mg, 9 mg or 17.2 mg (tablet doses) | once-daily · oral · 72 weeks | Human RCTn = 616 | Obesity pillars 2026, PMID 42577069 |
| 6 mg, 12 mg or 36 mg | once-daily · oral · 72 weeks | Human RCTn = 3127 | The New England journal of medicine 2025, PMID 40960239 |
| 3 mg, 12 mg or 36 mg | once daily · oral · 40 weeks | Human RCTn = 559 | The New England journal of medicine 2025, PMID 40544435 |
| 3 to 45 mg | once daily · oral · 26 weeks (diabetes study) or 36 weeks (obesity study) | Human RCTn = 595 | Cardiovascular diabetology 2025, PMID 40481478 |
| 3 mg single dose (study A); 16 mg multiple doses (study B) | oral | Human RCTn = 46 | Diabetes therapy 2024, PMID 38402332 |
| 12, 24, 36, or 45 mg | once daily · oral · 36 weeks | Human RCTn = 272 | The New England journal of medicine 2023, PMID 37351564 |
| 3 mg to 45 mg (various cohorts) vs dulaglutide 1·5 mg | once per day · oral · 26 weeks | Human RCTn = 383 | Lancet 2023, PMID 37369232 |
| single 0.3-6 mg; multiple 2-24 mg | single dose; daily for 4 weeks · oral · 4 weeks | Human RCTn = 92 | Diabetes, obesity & metabolism 2023, PMID 37344954 |
| 1 mg oral capsule with IV microtracer; 3 mg oral solution | single dose · oral and intravenous | Human uncontrolled trial | Clinical pharmacology in drug development 2026, PMID 40888509 |
Before anyone considers it
- Orforglipron is FDA approved (Foundayo, Apr 2026); research-chemical versions are not the approved drug.
- Compounded and research-chemical versions are not the approved product and are not checked by the FDA for identity, purity or dose.
- Reconstitution math (mg vs mcg, units vs mL) is the most asked question in peptide forums. Check every number twice.
- People who are pregnant, breastfeeding, or have a chronic condition need medical advice first.
Common questions
Is Orforglipron FDA approved?
Orforglipron is FDA approved (Foundayo, Apr 2026). Products sold as research chemicals are not the approved drug and are not checked by the FDA.
More on Orforglipron
Side effectsWhat labels and studies report, and what is unknown.ResultsStudy outcomes and when they were measured.PricePrice per mg and per week from dated listings. No vendor links.Legal statusFDA, compounding and WADA status with dates.For weight lossWhat research says about Orforglipron for weight loss.
Sources
- 1FDA approves first new molecular entity under National Priority Voucher program (Foundayo, orforglipron), 1 Apr 2026U.S. Food and Drug Administration · 2026fda.govAccessed 2 Oct 2026
- 2Metric (SI) Prefixes (NIST Reference on Constants, Units, and Uncertainty)National Institute of Standards and Technology (NIST) · 2025physics.nist.govAccessed 2 Oct 2026
- 3BASAGLAR (insulin glargine) injection, prescribing information (DailyMed)U.S. Food and Drug Administration / DailyMed (Eli Lilly and Company label) · 2026dailymed.nlm.nih.govAccessed 2 Oct 2026
- 4These highlights do not include all the information needed to use FOUNDAYO safely and effectively. See full prescribing information for FOUNDAYO. FOUNDAYO (orforglipron) tablets, for oral use Initial FDA label (Foundayo), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 5Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial.Lancet (London, England) · 2026PMID 41275875Accessed 2 Oct 2026
- 6Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial.Lancet (London, England) · 2026PMID 41765029Accessed 2 Oct 2026
- 7Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, randomised, non-inferiority, open-label, phase 3 trial.Lancet (London, England) · 2026PMID 42259339Accessed 2 Oct 2026
- 8Orforglipron for obesity treatment in older patients ≥65 years with or without type 2 diabetes: A post hoc subgroup analysis of the ATTAIN-1 and ATTAIN-2 trials.Obesity pillars · 2026PMID 42577069Accessed 2 Oct 2026
- 9Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.The New England journal of medicine · 2025PMID 40960239Accessed 2 Oct 2026
- 10Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes.The New England journal of medicine · 2025PMID 40544435Accessed 2 Oct 2026
- 11Treatment with orforglipron, an oral glucagon like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetes.Cardiovascular diabetology · 2025PMID 40481478Accessed 2 Oct 2026
- 12Effect of Food Consumption on the Pharmacokinetics, Safety, and Tolerability of Once-Daily Orally Administered Orforglipron (LY3502970), a Non-peptide GLP-1 Receptor Agonist.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2024PMID 38402332Accessed 2 Oct 2026
- 13Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.The New England journal of medicine · 2023PMID 37351564Accessed 2 Oct 2026
- 14Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study.Lancet (London, England) · 2023PMID 37369232Accessed 2 Oct 2026
- 15Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants.Diabetes, obesity & metabolism · 2023PMID 37344954Accessed 2 Oct 2026
- 16Disposition and Absolute Bioavailability of Orally Administered Orforglipron in Healthy Participants.Clinical pharmacology in drug development · 2026PMID 40888509Accessed 2 Oct 2026
Found an error? Report a correction.